Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy Venus Remedies is among the largest Indian exporters of these drugs Ukraine is among the largest countries in Europe and its pharmaceutical market has been witnessing
Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF This achievement is an endorsement of Venus Remedies' commitment to delivering top-quality pharmaceutical products worldwide Venus Remedies Limited, a leading global pharmaceutical company, has recently secured
The disbursement will bolster the company’s manufacturing capabilities and foster product diversification, including complex generics The grant emphasises the company’s commitment to driving innovation, entitles it to incentives for incremental sales of eligible pharmaceutical products Venus Remedies Ltd, one of India’s leading manufacturers of generic
Venus Remedies has secured regulatory approval from Philippines for chemotherapy medication paclitaxel and zoledronic acid, a drug used to treat metabolic bone disorders The company has also received marketing authorisation for another chemotherapy drug, bleomycin, from Saudi Arabia While Saudi Arabia is the largest
Obtaining market authorization for Bleomycin from MHRA is a momentous accomplishment for Venus Pharma GmbH. Venus Remedies holds a total of 15 Market Authorizations (MA) for Bleomycin products across the globe. Venus Remedies is thrilled to announce the achievement of market authorization in the United Kingdom
The $4.20-billion pharmaceutical market of the Philippines accounts for a significant market for Venus Remedies from the ASEAN region as the company moves a step closer towards emerging as the top oncology medicine supplier from India in Southeast Asia Venus Remedies’ oncology wing has
The Ecuador antibiotics market is majorly dependent on imports from India. Ecuador had imported antibiotics worth US $3.5 million in 2022. The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in
The company expects this marketing approval to enable it to rapidly expand its operations not only in Saudi Arabia, the largest pharma market in GCC region, but other GCC and MENA countries as well The marketing authorisation from Saudi Arabia comes as an evident
The company has consolidated its position in ASEAN, South America and Eastern Europe regions Venus Remedies has taken another decisive step towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region with the product registration from
The company has consolidated its position in GCC, ASEAN, Balkan and Caribbean regions with marketing approvals from Oman, Malaysia, Bosnia and Trinidad & Tobago for important chemotherapy drugs With this, the number of marketing approvals for its oncology products across 75 countries has gone
